Physicians' attitudes towards office-based delivery of methadone maintenance therapy: results from a cross-sectional survey of Nova Scotia primary-care physicians

Harm Reduction Journal

Volumn 9, Issue , 2012, Pages

  Dooley, Jessica ^a   Asbridge, Mark ^a   Fraser, John ^b   Kirkland, Susan ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b North End Community Health Centre   (Canada)

Author keywords

Access; Barriers; Methadone Maintenance Therapy (MMT); Office based delivery; Primary care physicians

Indexed keywords

METHADONE;

ADULT; ARTICLE; CANADA; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG USE; E-MAIL; FEMALE; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HUMAN; MAINTENANCE THERAPY; MALE; MEDICAL EDUCATION; PHYSICIAN ATTITUDE; PRESCRIPTION; PROFESSIONAL KNOWLEDGE;

EID: 84862222854     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-9-20     Document Type: Article

References (43)

1. Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health 2006, 120:320-328. 10.1016/j.puhe.2005.09.010, 16476455.
2. Rehm J, Baliuna D, Brochu S, Fischer B, Gnam W, Patra J, Popova S, Sarnocinska-Hart A, Taylor B. The costs of substance abuse in Canada 2002 2006, Canadian Centre on Substance Abuse, Ottawa, ON.
3. Fischer B, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noel L, Rehm J, Tyndall M, Wild C, Mun P, Haydon E, Baliunas D. Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. Can Med Assoc J 2004, 171(3):235-239.
4. Hser Y, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotic addicts. Arch Gen Psychiatry 2001, 58:503-508. 10.1001/archpsyc.58.5.503, 11343531.
5. Millson P, Challacombe L, Villeneuve PJ, Fischer B, Strike CJ, Myers T, Shore R, Hopkins S, Raftis S, Pearson M. Self-perceived health among Canadian opiate users. Can J Public Health 2004, 95(2):99-104.
6. Novick DM, Richman BL, Friedman JM, Friedman JE, Fried C, Wilson JP, Townley A, Kreek MJ. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug Alcohol Depend 1993, 33(3):235-245. 10.1016/0376-8716(93)90110-C, 8261888.
7. Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. J Am Med Assoc 1973, 223(6):665-668.
8. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993, 119(1):23-27.
9. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000, 77(3):331-345. 10.1007/BF02386744, 10976608.
10. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 2003, 72(1):59-65. 10.1016/S0376-8716(03)00187-X, 14563543.
11. Gossop M, Marsden J, Stewart D, Kidd T. The national treatment outcome research study (NTORS): 4-5 year follow-up results. Addiction 2003, 98:291-303. 10.1046/j.1360-0443.2003.00296.x, 12603229.
12. Willner-Reid J, Belendiuk KA, Epstein DH, Schmittner J, Preston KL. Hepatitis C and HIV risk behaviour in polydrug users on methadone maintenance. J Subst Abuse Treat 2008, 35(1):78-86. 10.1016/j.jsat.2007.08.011, 2600879, 17931826.
13. Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, Shore R, Hopkins S. Reduction in injection-related HIV risk after 6 months in a low-threshold methadone treatment program. AIDS Educ Prev 2007, 19(2):124-136. 10.1521/aeap.2007.19.2.124, 17411415.
14. Canadian Press, May 13, 2011. " Nova Scotia government to expand methadone treatment after drug-related deaths." http://www.ipolitics.ca/2011/05/13/nova-scotia-government-to-expand-methadone-treatment-after-drug-related-deaths/.
15. Nova Scotia Addiction Services 2009-2010 Annual Report 2011, Nova Scotia Department of Health and Wellness, Halifax.
16. Byrne A, Wodak A. Census of patients receiving methadone treatment in a general practice. Addict Res 1996, 3(4):341-349.
17. Greenwood J. Persuading general practitioners to prescribe - good husbandry or recipe for chaos?. Br J Addict 1992, 87:567-575. 10.1111/j.1360-0443.1992.tb01958.x, 1591510.
18. Van Brussel G. Methadone treatment in Amsterdam: The critical role of general practitioners. Addict Res 1996, 3(4):363-368.
19. Novick DM, Joseph H, Salsitz EA, Kalin MF, Keefe JB, Miller EL, Richman BL. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): Follow-up at three and a half to nine and a fourth years. J Gen Intern Med 1994, 9(3):127-130. 10.1007/BF02600025, 8195910.
20. Latowsky M, Kallen E. Mainstreaming methadone maintenance treatment: The role of the family physician. Can Med Assoc J 1997, 157(4):395-398.
21. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: A randomized controlled trial. JAMA 2001, 286(14):1724-1731. 10.1001/jama.286.14.1724, 11594897.
22. Salsitz EA, Joseph H, Frank B, Perez J, Richman BL, Saloman N, Kalin MF, Novick DM. Methadone medical maintenance (MMM): Treating chronic opioid dependence in private medical practice - A summary report (1983-1998). Mt Sinai J Med 2000, 67(5&6):388-397.
23. Fischer B, Rehm J, Patra J, Crus MF. Change in illicit opioid use across Canada. CMAJ 2006, 175(11):1385-1387. 10.1503/cmaj.060729, 1635767, 17116905.
24. Best practices - methadone maintenance treatment. No. H49-164/2002E 2002, Health Canada, Ottawa, ON.
25. Anderson JF. Methadone maintenance: BC leads the way. Can Med Assoc J 1997, 157(9):1198.
26. Fischer B, Cape D, Daniel N, Gliksman L. Methadone treatment in Ontario after the 1996 regulation reforms. Ann Med Intern 2002, 153(7):2S11-2S21.
27. Gossop M, Marsden J, Stewart D, Lehmann P, Strang J. Methadone treatment practices and outcome for opiate addicts in drug clinics and in general practice results from the national treatment outcome research study. Br J Gen Pract 1999, 49:31-34. 1313314, 10622013.
28. Jones ES, Moore BA, Sindelarc JL, O'Connora PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009, 99:132-140. 10.1016/j.drugalcdep.2008.07.013, 2646001, 18804923.
29. van Brussel G. Methadone treatment by general practitioners in Amsterdam. Bull N Y Acad Med 1995, 72(2):348-358. 2359435, 10101375.
30. Rossi PH, Wright JD, Anderson AB. Handbook of survey research 1983, Academic, New York.
31. Streiner DL, Norman GR. Health measurement scales: A practical guide to their development and use 1989, Oxford University Press, Oxford.
32. Caplehorn JRM, Irwig L, Saunders JB. Attitudes and beliefs of staff working in methadone maintenance clinics. Subst Use Misuse 1996, 31(4):437-452. 10.3109/10826089609045820, 8851811.
33. Gjersing LR, Butler T, Caplehorn J, Belcher JM, Matthews R. Attitudes and beliefs towards methadone maintenance treatment among Australian prison health staff. Drug and Alcohol Review 2007, 26:501-508. 10.1080/09595230701499118, 17701513.
34. McKeown A, Matheson C, Bond C. A qualitative study of GPs' attitudes to drug misusers and drug misuse services in primary care. Family Practice 2002, 20(2):120-125.
35. McGillion J, Wanigaratne S, Feinmann C, Godden T, Byrne A. GPs' attitudes towards the treatment of drug misusers. Br J Gen Pract 2000, 50:385-386. 1313703, 10897536.
36. Pelet A, Doll S, Huissoud T, Resplendino J, Besson J, Favrat B. Methadone maintenance treatment in the Swiss Canton of Vaud: demographic and clinical data on 1,782 ambulatory patients. Eur Addict Res 2005, 11:99-106. 10.1159/000083039, 15785071.
37. Hobden KL, Cunningham JA. Barriers to the dissemination of four harm reduction strategies: A survey of addiction treatment providers in Ontario. Harm Reduct J 2006, 3(35):1-20. 10.1186/1477-7517-3-35, 1368973, 16403229.
38. Ogborne AC, Birchmore-Timney C. Support for harm-reduction among staff of specialized treatment services in Ontario, Canada. Drug Alcohol Rev 1998, 17(1):51-58. 10.1080/09595239800187591, 16203468.
39. Ogborne AC, Wild CT, Braun K, Newton-Taylor B. Measuring treatment process beliefs among staff of specialized addiction treatment services. J Subst Abuse Treat 1998, 15(4):301-312. 10.1016/S0740-5472(97)00196-7, 9650138.
40. Ruch JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, Friedmann PD. Attitudes and practices regarding the use of methadone in US and state federal prisons. J Urban Health 2005, 82(3):411-418. 10.1093/jurban/jti072, 15917502.
41. Weber EM. Failure of physicians to prescribe pharmacotherapies for addiction: regulatory restrictions and physician resistance. J Health Care L & Pol'y 2010, 13(1):49.
42. Strang J, Manning V, Mayet S, Ridge G, Best D, Sheridan J. Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995-2005. Addiction 2007, 102(5):761-770. 10.1111/j.1360-0443.2007.01762.x, 17506153.
43. http://www.nationalphysiciansurvey.ca/nps/2007_Survey/2007nps-e.asp